STAT

2018 in limericks: The highs and lows from the life sciences

What a year it's been in the life sciences: CRISPR babies and IPOs galore, high-priced CAR-Ts and gene therapies. We remember it all with the 2018 edition of our year…

It’s been an eventful year in the life sciences, from the struggles of IBM Watson, to China’s twin CRISPR surprise, to a flurry of IPOs, to catching a serial killer with.)

You're reading a preview, sign up to read more.

More from STAT

STAT7 min readTech
One Health Care Startup At A Time, This Venture Capitalist Wants To Harness The Investing Power Of Women
“If women want specific companies in the world that address their needs, the only way to do that is for women to become the investors."
STAT4 min readSociety
Opinion: Bringing Transparency To The Notion Of Price Transparency
Transparency is not just a goal. It's also an ethic. Organizations involved in price transparency initiatives should be transparent in the ways appropriate to them.
STAT1 min read
Listen: The Serious Side Of Spit Kits, How BiTEs Leave A Mark, & Sarepta’s Sluggish Study
Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Fi